Scientists at the University of Bradford (link is external), along with colleagues in the USA and Finland*, have created a modified version of the cancer drug temozolomide**, the first-line treatment for glioblastoma.
The Cancer Research UK team has shown in the laboratory that the revamped drug – called DP68 – is better than temozolomide at killing cancer cells. And it significantly reduced the regrowth of tumour cells that had become resistant to temozolomide.
“It’s still early days but, unlike temolozomide that’s only used to treat gliomas, we hope this new version of the drug may benefit patients with other cancer types” – Dr Richard Wheelhouse, study author
Glioblastomas account for more than a quarter*** of all primary brain tumours, with around 2,500 people diagnosed with the disease every year in the UK.
Cancer Research UK led on the development of temozolomide, which marked an important breakthrough in the treatment of glioblastoma. It has become the international standard of care for thousands of patients with this type of cancer. But in many cases the cancer cells become resistant. And, once the disease returns, it is very hard to treat.
Study author, Dr Richard Wheelhouse, based at the University of Bradford, said: “Temozolomide is a widely-used treatment for patients with glioblastoma. But, when resistance to the drug develops, the tumours often grow back more aggressively so it’s crucial to find new ways of outmanoeuvring the cancer cells.
“DP68 could become a vital treatment for glioblastoma patients who’ve developed resistance to the first-line treatment. It’s still early days but, unlike temolozomide that’s only used to treat gliomas, we hope this new version of the drug may benefit patients with other cancer types.”
Professor Peter Johnson, Cancer Research UK’s chief clinician, said: “We still need to do much more research in the treatment of brain tumours, where progress has been painfully slow. It is very encouraging to think that this drug might be helpful for people whose cancer stops responding to treatment. Innovative research like this is crucial to find vital new treatments to improve survival.”
For media enquiries please contact the press office on 020 3469 8300 or, out-of-hours, the duty press officer on 07050 264 059.
Yulian P. Ramirez, et al., Evaluation of Novel Imidazotetrazine Analogues Designed to Overcome Temozolomide Resistance and Glioblastoma Regrowth.
Notes to Editor
* Researchers based at the University of Bradford; Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, USA; Department of Radiation Oncology, Mayo Clinic, Rochester, USA; School of Pharmacy, University of Eastern Finland.
** Temozolomide (Temodal) is a chemotherapy drug used to treat brain tumours. It is a type of drug known as an alkylating agent and works by stopping cancer cells from making new DNA.
*** Proportion of brain, other CNS and intracranial tumours in England in 2006-2010 which were glioblastomas (around 27%) applied to total brain, other CNS and intracranial tumours in the UK, 2011.